Skip to product information
1 of 1

Quidel Respiratory Test Kit Solana® SARS-CoV-2 96 Tests CLIA Non-Waived - KT/1 - M958-KT

Quidel Respiratory Test Kit Solana® SARS-CoV-2 96 Tests CLIA Non-Waived - KT/1 - M958-KT

Regular price $6,143.99
Sale price $6,143.99 Regular price
OFF Sold out
Shipping calculated at checkout.

50 In stock

Estimated deliver:

Flat-Rate Shipping from $8.25

  • American Express
  • Diners Club
  • Discover
  • Mastercard
  • Shop Pay
  • Visa
View full details
Reviews

Quidel Respiratory Test Kit Solana® SARS-CoV-2 96 Tests CLIA Non-Waived - KT/1 - M958-KT

Item Id 1182301
MF Id# M958
Brand Solana®
Manufacturer Quidel
Country of Origin United States
Application Respiratory Test Kit
CLIA Classified CLIA Non-Waived
Contents 1 (96) Process Buffer Tubes, (96) Empty Reaction Tubes, 1 Tube Negative Control, 1 Tube Positive Control, (8) Master Mix Tubes, (100) Nasal Swabs, (100) Universal Transport Media
For Use With For use with Solana Instrument
HCPCS U0002 (Disclaimer)
Is_Active_Vendor Y
Is_DSCSA N
Is_Discontinued N
Is_Medical_Device N
Lot_Tracking_Flag N
Number of Tests 96 Tests
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 90 days
Purchase Program Type Standard Purchase
Reading Type Machine Read
Sample Type Nasal Swab Sample
Specialty Molecular
Storage Requirements Keep Frozen
Supplier_ID 487993
Test Format Tube Format
Test Kit Type Standard
Test Method Isothermal Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA) Assay
Test Name SARS-CoV-2
Test Type Molecular Diagnostic
Time to Results 30 Minute Results
UNSPSC Code 41116144

Features

  • Solana SARS-CoV-2 Assay is for use under an FDA Emergency Use Authorization: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high or moderate complexity tests
  • The Solana SARS-CoV-2 Assay is an isothermal Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal (NP) and nasal (NS) swab specimens from individuals suspected of COVID-19 by their healthcare provider
  • Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status
  • Positive results do not rule out bacterial infection or co-infection with other viruses
  • Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities
  • Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions; negative results must be combined with clinical observations, patient history, and epidemiological information
  • The Solana SARS-CoV-2 Assay is intended for use by laboratory personnel who have received specific training on the use of the Solana SARS-CoV-2 Assay and/or the Solana Instrument
  • The assay consists of two major steps: (1) specimen preparation, and (2) amplification and detection of target sequences specific to SARS-CoV-2 using isothermal Reverse Transcriptase — Helicase-Dependent Amplification (RT-HDA) in the presence of target-specific fluorescence probes which is performed in the Solana instrument
About your query!
Recently Viewed